BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31487676)

  • 1. PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment.
    Chen JA; Esteghamat N; Kim EJ; Garcia G; Gong J; Fakih MG; Bold RJ; Cho MT
    J Natl Compr Canc Netw; 2019 Sep; 17(9):1026-1030. PubMed ID: 31487676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
    Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
    Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
    Sobecki-Rausch J; Barroilhet L
    Curr Treat Options Oncol; 2019 Nov; 20(11):83. PubMed ID: 31754884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
    Ghiringhelli F; Fumet JD
    Front Immunol; 2019; 10():1816. PubMed ID: 31447840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
    Zhao P; Li L; Jiang X; Li Q
    J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.
    Gong J; Robertson MD; Kim E; Fakih M; Schrock AB; Tam KW; Burugapalli B; Monjazeb AM; Hendifar AE; Hitchins M; Klempner SJ; Cho M
    Clin Colorectal Cancer; 2019 Dec; 18(4):307-309. PubMed ID: 31563511
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy of Colon Cancer.
    Stein A; Folprecht G
    Oncol Res Treat; 2018; 41(5):282-285. PubMed ID: 29705788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
    Lee V; Murphy A; Le DT; Diaz LA
    Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system.
    Hirsch D; Gaiser T; Merx K; Weingaertner S; Forster M; Hendricks A; Woenckhaus M; Schubert T; Hofheinz RD; Gencer D
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):263-273. PubMed ID: 32776177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
    Tintelnot J; Stein A
    World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
    Overman MJ; Ernstoff MS; Morse MA
    Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease Receiving Steroid Therapy.
    Massucci M; Di Fabio F; Rojas Llimpe FL; Ardizzoni A
    J Immunother; 2020 Jun; 43(5):153-155. PubMed ID: 31913208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.
    Llosa NJ; Luber B; Siegel N; Awan AH; Oke T; Zhu Q; Bartlett BR; Aulakh LK; Thompson ED; Jaffee EM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Housseau F; Anders RA
    Cancer Immunol Res; 2019 Oct; 7(10):1574-1579. PubMed ID: 31439614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
    Gong J; Wang C; Lee PP; Chu P; Fakih M
    J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.